Robert Hamilton Pierce net worth and biography

Robert Pierce Biography and Net Worth

Robert Pierce, M.D. has served as our Chief Scientific Officer since March 2020. Prior to joining us, Dr. Pierce served as Scientific Director of the Immunopathology Lab in the Clinical Research Division of the Fred Hutchinson Cancer Research Center from November 2016 until March 2020. Prior to that, Dr. Pierce served as Chief Scientific Officer of OncoSec Medical Incorporated, a biotechnology company, from 2014 until June 2016. Dr. Pierce received a B.A. in Philosophy from Yale College and an M.D. from Brown University.

How do I contact Robert Hamilton Pierce?: The corporate mailing address for Dr. Pierce and other Sensei Biotherapeutics executives is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. Sensei Biotherapeutics can also be reached via phone at 240-243-8000 and via email at [email protected]. Learn More on Robert Hamilton Pierce's contact information.
Has Robert Hamilton Pierce been buying or selling shares of Sensei Biotherapeutics?: Robert Hamilton Pierce has not been actively trading shares of Sensei Biotherapeutics during the last quarter. Most recently, Robert Hamilton Pierce sold 16,030 shares of the business's stock in a transaction on Wednesday, August 11th. The shares were sold at an average price of $7.34, for a transaction totalling $117,660.20. Learn More on Robert Hamilton Pierce's trading history.
Who are Sensei Biotherapeutics' active insiders?: Sensei Biotherapeutics' insider roster includes James Peyer (Director), Robert Pierce (Insider), and Thomas Ricks (Director). Learn More on Sensei Biotherapeutics' active insiders.
Are insiders buying or selling shares of Sensei Biotherapeutics?: During the last year, Sensei Biotherapeutics insiders bought shares 1 times. They purchased a total of 500 shares worth more than $425.00. During the last year, insiders at the sold shares 1 times. They sold a total of 3,441,661 shares worth more than $5,437,824.38. The most recent insider tranaction occured on September, 11th when CEO John Celebi bought 500 shares worth more than $425.00. Insiders at Sensei Biotherapeutics own 25.5% of the company. Learn More about insider trades at Sensei Biotherapeutics.
Information on this page was last updated on 9/11/2023.

Robert Hamilton Pierce Insider Trading History at Sensei Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/11/2021	Sell	16,030	$7.34	$117,660.20
8/9/2021	Sell	6,982	$7.06	$49,292.92
8/6/2021	Sell	6,460	$7.11	$45,930.60

Robert Hamilton Pierce Buying and Selling Activity at Sensei Biotherapeutics

Sensei Biotherapeutics Company Overview

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Today's Range

Now: $0.99

$0.94

$1.04

50 Day Range

MA: $0.96

$0.76

$1.17

2 Week Range

Now: $0.99

$0.51

$1.72

Volume

54,562 shs

Average Volume

64,946 shs

Market Capitalization

$24.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…